Omeprazole/amoxicillin/rifabutin

Omeprazole/amoxicillin/rifabutin

Combination of
Omeprazole	Proton-pump inhibitor
Amoxicillin	Penicillin-class antibacterial
Rifabutin	Rifamycin antibacterial
Clinical data
Trade names	Talicia
AHFS/Drugs.com	Professional Drug Facts
License data	US  DailyMed:  Omeprazole_magnesium,_amoxicillin_and_rifabutin
Routes of administration	By mouth
ATC code	A02BD16 ( WHO )
Legal status
Legal status	US: ℞-only [1]
Identifiers
KEGG	D11858

Omeprazole/amoxicillin/rifabutin, sold under the brand name Talicia, is a fixed-dose combination medication used for the treatment of Helicobacter pylori infection. ^[1] It is taken by mouth. ^[1]

It was approved for medical use in the United States in November 2019. ^[2]

References

1. "Talicia- omeprazole magnesium, amoxicillin and rifabutin capsule, delayed release". DailyMed. Retrieved 4 October 2021.
2. "Drug Approval Package: Talicia". U.S. Food and Drug Administration (FDA). 9 April 2020. Retrieved 4 October 2021.

External links

• "Omeprazole". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 23 November 2016.
• "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 1 December 2016.
• "Rifabutin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 27 August 2018.
• Clinical trial number NCT03198507 for "ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2)" at ClinicalTrials.gov
• Clinical trial number NCT01980095 for "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (ERADICATE Hp)" at ClinicalTrials.gov